Watch the latest episode of focusIR Fireside Chats: Why Edinburgh Investment Trust Is Backing Turnaround Stocks for 2026 Growth. View here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksPHC.L Regulatory News (PHC)

  • There is currently no data for PHC

Director/PDMR Shareholding

15 Jul 2013 17:15

RNS Number : 3688J
Plant Health Care PLC
15 July 2013
 



15 July 2013

 

PLANT HEALTH CARE PLC("Plant Health Care" or the "Company")

 

Director's dealing

 

Plant Health Care (AIM / CISX: PHC.L) announces that it has entered into a binding agreement with Mr John Brady, a director of the Company. Under the agreement, Mr Brady shall exercise, in two equal tranches on 15 October 2013 and 13 November 2013 all of his options over unissued shares in the Company, which equate to 975,000 Plant Health Care shares ("Shares"). On each date Mr Brady shall sell such number of Shares as is sufficient to cover the exercise price and his associated tax liability arising from the exercise. Any sale of Shares shall be at the prevailing market price and subject to sufficient demand in the market. Further details, using the assumptions specified so as to provide working examples, are set out below:

 

15 October 2013

Mr Brady shall exercise 487,500 options at an exercise price of 37p per Share and sell such number of Shares as shall cover the amount of the aggregate exercise price and his associated tax liability. Assuming a prevailing Share price of 78.5p, being the closing Share price on 12 July 2013, the funds required to cover the exercise price and taxes would equate to approximately £261,000 which would require the disposal of approximately 332,485 Shares*.

 

13 November 2013

56,025 options with an exercise price of 71p per Share (provided they are below the then current market price) and sell such number of Shares as shall cover the amount of the aggregate exercise price and his associated tax liability. Assuming a prevailing share price of 78.5p, being the closing share price on 12 July 2013, the funds required to cover the exercise price and taxes would equate to approximately £274,000 which would require the disposal of approximately 349,045 Shares*.

 

 

 

Notes:

1. The closing share price of 78.5p refers to the closing middle market price of a Plant Health Care share on 12 July 2013 as derived from the daily official list of the London Stock Exchange plc.

2. *An exchange rate of £/$1.5118 has been assumed which was derived from data provided on FT.com by WM/Reuters as at 4.00 p.m. London time on 12 July 2013 (being the last practicable dealing date prior to the date of this announcement).

 

For further information please contact:

 

Plant Health Care plc

Dr. Chris Richards

Chairman

Tel: +44 (0)20 7250 1446

Nomura Code Securities

Clare Terlouw / Chris Golden

Tel: +44 (0)20 7776 1200

www.nomuracode.com

Powerscourt

Paul Durman / Sophie Moate

Tel: +44 (0)20 7250 1446

paul.durman@powerscourtgroup.

com

sophie.moate@powerscourtgroup

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
RDSSFUFIIFDSEIW
Date   Source Headline
28th Jun 202312:29 pmRNSHolding(s) in Company
27th Jun 20234:08 pmRNSHolding(s) in Company
27th Jun 20231:08 pmRNSDirector Shareholding
23rd Jun 20237:00 amRNSResult of Fundraising
22nd Jun 20234:35 pmRNSFundraising to raise up to US$3.6 million
14th Jun 20237:00 amRNSWilbur Ellis Agreement
13th Jun 20231:43 pmRNSResult of AGM
30th May 20237:00 amRNSHolding(s) in Company
24th May 20231:12 pmRNSHolding(s) in Company
19th May 20235:55 pmRNSPublication of Annual Report and Notice of AGM
18th May 20237:00 amRNSResult of Consultation
9th May 20237:00 amRNSPHC68949 granted first stage of approval in Brazil
2nd May 20237:10 amRNSResults for the year ended 31 December 2022
12th Apr 20232:33 pmRNSNotice of Results
5th Apr 20235:29 pmRNSHolding(s) in Company
8th Mar 20232:45 pmRNSExercise of Options
2nd Mar 20237:00 amRNSBiofungicide PHC279 Approved by US EPA
1st Mar 20237:00 amRNSDirector/PDMR Shareholding
6th Feb 20237:00 amRNSTrading Statement
30th Jan 202312:08 pmRNSSignificant Shareholder
18th Jan 20237:00 amRNSBoard Appointments
12th Jan 20237:00 amRNSNovozymes Distribution Agreement
9th Jan 20237:00 amRNSInvestor Presentation
22nd Dec 20227:00 amRNSNew Products Submitted for Regulatory Approval
28th Oct 20227:00 amRNSRegistration of Harpin in France
28th Oct 20227:00 amRNSNew distribution agreement with EDAF
27th Oct 20227:00 amRNSTrading Update
14th Oct 20225:11 pmRNSDirector/PDMR Shareholding
14th Oct 202210:39 amRNSDirector / PDMR Shareholding
26th Sep 20227:00 amRNSInterim Results
22nd Aug 20227:00 amRNSTrials agreement signed with Agrii UK
12th Aug 20227:00 amRNSGrant of Options
10th Aug 20225:04 pmRNSDirector/PDMR Shareholding
21st Jul 20222:41 pmRNSHolding(s) in Company
18th Jul 20227:02 amRNSInvestor Presentation
18th Jul 20227:00 amRNSPost-Close Trading Update
22nd Jun 202212:37 pmRNSResult of AGM
21st Jun 20227:00 amRNSCompletion of Nominated Adviser due diligence
20th Jun 20227:00 amRNSLong-term Harpin Production and Supply Agreement
6th Jun 20228:00 amRNSHolding(s) in Company
6th Jun 20228:00 amRNSHolding(s) in Company
1st Jun 20222:31 pmRNSDirector/PDMR Shareholding
25th May 20225:23 pmRNSHolding(s) in Company
23rd May 20227:30 amRNSAnnual Report & Accounts and Notice of AGM
23rd May 20227:00 amRNSNew distribution agreement with Nutrien
16th May 20227:00 amRNSHolding(s) in Company
12th May 20227:15 amRNSCEO appointment and Board changes
12th May 20227:00 amRNSResults for the year ended 31 December 2021
28th Apr 20227:00 amRNSChange of Adviser
21st Apr 20222:27 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.